Search

Your search keyword '"ter Elst, Arja"' showing total 217 results
Start Over Author "ter Elst, Arja"
217 results on '"ter Elst, Arja"'

1. Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study

Author

Eerkens, Anneke L., Brummel, Koen, Vledder, Annegé, Paijens, Sterre T., Requesens, Marta, Loiero, Dominik, van Rooij, Nienke, Plat, Annechien, Haan, Floris-Jan, Klok, Patty, Yigit, Refika, Roelofsen, Thijs, de Lange, Natascha M., Klomp, Rie, Church, David, ter Elst, Arja, Wardenaar, René, Spierings, Diana, Foijer, Floris, Koelzer, Viktor Hendrik, Bosse, Tjalling, Bart, Joost, Jalving, Mathilde, Reyners, Anna K. L., de Bruyn, Marco, and Nijman, Hans W.

Published
2024
Full Text
View/download PDF

3. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting

Author

van Opijnen, Mark P., Broekman, Marike L. D., Cuppen, Edwin, Dubbink, Hendrikus J., ter Elst, Arja, van Eijk, Ronald, Mühlebner, Angelika, Jansen, Casper, van der Geize, Robert, Speel, Ernst-Jan M., Groenen, Patricia J. T. A., de Vos, Filip Y. F., Wesseling, Pieter, de Leng, Wendy W. J., and Maas, Sybren L. N.

Published
2024
Full Text
View/download PDF

4. Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study

Author

Bleckman, Roos F., primary, Haag, Charlotte M. S. C., additional, Rifaela, Naomi, additional, Beukema, Gerrieke, additional, Mathijssen, Ron H. J., additional, Steeghs, Neeltje, additional, Gelderblom, Hans, additional, Desar, Ingrid M. E., additional, Cleven, Arjen, additional, ter Elst, Arja, additional, Schuuring, Ed, additional, and Reyners, Anna K. L., additional

Published
2024
Full Text
View/download PDF

5. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

Author

Zwierenga, Fenneke, van Veggel, Bianca, Hendriks, Lizza E.L., Hiltermann, T. Jeroen N., Hiddinga, Birgitta I., Hijmering Kappelle, Lucie B.M., ter Elst, Arja, Hashemi, Sayed M.S., Dingemans, Anne-Marie C., van der Leest, Cor, de Langen, Adrianus J., van den Heuvel, Michel M., and van der Wekken, Anthonie J.

Published
2022
Full Text
View/download PDF

6. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature

Author

Koopman, Bart, Groen, Harry J.M., Schuuring, Ed, Hiltermann, T. Jeroen N., Timens, Wim, den Dunnen, Wilfred F.A., van den Berg, Anke, ter Elst, Arja, van Kruchten, Michel, Kluiver, Joost L., Hiddinga, Birgitta I., Hijmering-Kappelle, Lucie B.M., Groves, Matthew R., Vilacha, Juliana F., van Kempen, Léon C., and van der Wekken, Anthonie J.

Published
2022
Full Text
View/download PDF

8. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands:interlaboratory variation in the primary diagnostic and recurrent setting

Author

van Opijnen, Mark P., Broekman, Marike L.D., Cuppen, Edwin, Dubbink, Hendrikus J., ter Elst, Arja, van Eijk, Ronald, Mühlebner, Angelika, Jansen, Casper, van der Geize, Robert, Speel, Ernst Jan M., Groenen, Patricia J.T.A., de Vos, Filip Y.F., Wesseling, Pieter, de Leng, Wendy W.J., Maas, Sybren L.N., van Opijnen, Mark P., Broekman, Marike L.D., Cuppen, Edwin, Dubbink, Hendrikus J., ter Elst, Arja, van Eijk, Ronald, Mühlebner, Angelika, Jansen, Casper, van der Geize, Robert, Speel, Ernst Jan M., Groenen, Patricia J.T.A., de Vos, Filip Y.F., Wesseling, Pieter, de Leng, Wendy W.J., and Maas, Sybren L.N.

Abstract

Purpose: Next generation sequencing (NGS) is an important tool used in clinical practice to obtain the required molecular information for accurate diagnostics of high-grade adult-type diffuse glioma (HGG). Since individual centers use either in-house produced or standardized panels, interlaboratory variation could play a role in the practice of HGG diagnosis and treatment. This study aimed to investigate the current practice in NGS application for both primary and recurrent HGG. Methods: This nationwide Dutch survey used the expertise of (neuro)pathologists and clinical scientists in molecular pathology (CSMPs) by sending online questionnaires on clinical and technical aspects. Primary outcome was an overview of panel composition in the different centers for diagnostic practice of HGG. Secondary outcomes included practice for recurrent HGG and future perspectives. Results: Out of twelve neuro-oncology centers, the survey was filled out by eleven (neuro)pathologists and seven CSMPs. The composition of the diagnostic NGS panels differed in each center with numbers of genes ranging from 12 to 523. Differences are more pronounced when tests are performed to find therapeutic targets in the case of recurrent disease: about half of the centers test for gene fusions (60%) and tumor mutational burden (40%). Conclusion: Current notable interlaboratory variations as illustrated in this study should be reduced in order to refine diagnostics and improve precision oncology. In-house developed tests, standardized panels and routine application of broad gene panels all have their own advantages and disadvantages. Future research would be of interest to study the clinical impact of variation in diagnostic approaches.

Published
2024

9. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting

Author

CMM Groep Van Mil, Pathologie Pathologen staf, Brain, Cancer, MS Medische Oncologie, Pathologie Groep Van Diest, van Opijnen, Mark P, Broekman, Marike L D, Cuppen, Edwin, Dubbink, Hendrikus J, Ter Elst, Arja, van Eijk, Ronald, Mühlebner, Angelika, Jansen, Casper, van der Geize, Robert, Speel, Ernst-Jan M, Groenen, Patricia J T A, de Vos, Filip Y F, Wesseling, Pieter, de Leng, Wendy W J, Maas, Sybren L N, CMM Groep Van Mil, Pathologie Pathologen staf, Brain, Cancer, MS Medische Oncologie, Pathologie Groep Van Diest, van Opijnen, Mark P, Broekman, Marike L D, Cuppen, Edwin, Dubbink, Hendrikus J, Ter Elst, Arja, van Eijk, Ronald, Mühlebner, Angelika, Jansen, Casper, van der Geize, Robert, Speel, Ernst-Jan M, Groenen, Patricia J T A, de Vos, Filip Y F, Wesseling, Pieter, de Leng, Wendy W J, and Maas, Sybren L N

Published
2024

10. Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Author

Wei, Jiacong, Meng, Pei, Terpstra, Miente Martijn, van Rijk, Anke, Tamminga, Menno, Scherpen, Frank, ter Elst, Arja, Alimohamed, Mohamed Z., Johansson, Lennart F., Stigt, Jos, Gijtenbeek, Rolof P. G., van Putten, John, Hiltermann, T. Jeroen N., Groen, Harry J. M., Kok, Klaas, van der Wekken, Anthonie J., and van den Berg, Anke

Published
2021
Full Text
View/download PDF

11. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics

Author

Eijkelenboom, Astrid, Tops, Bastiaan B. J., van den Berg, Anke, van den Brule, Adrianus J. C., Dinjens, Winand N. M., Dubbink, Hendrikus J., ter Elst, Arja, Geurts-Giele, Willemina R. R., Groenen, Patricia J. T. A., Groenendijk, Floris H., Heideman, Daniëlle A. M., Huibers, Manon M. H., Huijsmans, Cornelis J. J., Jeuken, Judith W. M., van Kempen, Léon C., Korpershoek, Esther, Kroeze, Leonie I., de Leng, Wendy W. J., van Noesel, Carel J. M., Speel, Ernst-Jan M., Vogel, Maartje J., van Wezel, Tom, Nederlof, Petra M., Schuuring, Ed, and Ligtenberg, Marjolijn J. L.

Published
2019
Full Text
View/download PDF

13. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material

Author

Steeghs, Elisabeth M. P., Kroeze, Leonie I., Tops, Bastiaan B. J., van Kempen, Leon C., ter Elst, Arja, Kastner-van Raaij, Annemiek W. M., Hendriks-Cornelissen, Sandra J. B., Hermsen, Mandy J. W., Jansen, Erik A. M., Nederlof, Petra M., Schuuring, Ed, Ligtenberg, Marjolijn J. L., and Eijkelenboom, Astrid

Published
2020
Full Text
View/download PDF

22. Data from VEGFC Antibody Therapy Drives Differentiation of AML

Author

Kampen, Kim R., primary, Scherpen, Frank J.G., primary, Mahmud, Hasan, primary, ter Elst, Arja, primary, Mulder, André B., primary, Guryev, Victor, primary, Verhagen, Han J.M.P., primary, De Keersmaecker, Kim, primary, Smit, Linda, primary, Kornblau, Steven M., primary, and De Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 3 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 2 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 3 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 2 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 1 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 1 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 4 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 4 from Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

Author

Sikkema, Arend H., primary, Diks, Sander H., primary, den Dunnen, Wilfred F.A., primary, ter Elst, Arja, primary, Scherpen, Frank J.G., primary, Hoving, Eelco W., primary, Ruijtenbeek, Rob, primary, Boender, Piet J., primary, de Wijn, Rik, primary, Kamps, Willem A., primary, Peppelenbosch, Maikel P., primary, and de Bont, Eveline S.J.M., primary

Published
2023
Full Text
View/download PDF

36. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC:Results from the phase 2 multicenter POSITION20 trial

Author

Zwierenga, Fenneke, van Veggel, Bianca, Hendriks, Lizza E.L., Hiltermann, T. Jeroen N., Hiddinga, Birgitta I., Hijmering Kappelle, Lucie B.M., ter Elst, Arja, Hashemi, Sayed M.S., Dingemans, Anne Marie C., van der Leest, Cor, de Langen, Adrianus J., van den Heuvel, Michel M., van der Wekken, Anthonie J., Zwierenga, Fenneke, van Veggel, Bianca, Hendriks, Lizza E.L., Hiltermann, T. Jeroen N., Hiddinga, Birgitta I., Hijmering Kappelle, Lucie B.M., ter Elst, Arja, Hashemi, Sayed M.S., Dingemans, Anne Marie C., van der Leest, Cor, de Langen, Adrianus J., van den Heuvel, Michel M., and van der Wekken, Anthonie J.

Abstract

Introduction: Patients with life-threatening advanced non-small cell lung cancer (NSCLC) who harbor an exon 20 deletion and/or insertion mutation (EGFRex20 + ) have limited effective treatment options. The high dose 3rd generation tyrosine kinase inhibitor (TKI) osimertinib shows promising in vitro activity in EGFRex20 + NSCLC tumors. Methods: The POSITION20 is a single arm phase II, multicenter study investigating 160 mg osimertinib in patients with EGFRex20+, T790M negative NSCLC. We allowed patients to be treatment naïve and to have asymptomatic brain metastases. The primary endpoint was overall response rate (ORR). Secondary outcomes were duration of response (DoR), progression free survival (PFS), overall survival (OS), and treatment related adverse events (trAEs). Results: From June 2018 to October 2021, 25 patients were enrolled across five centers in the Netherlands. The median age was 70 years (range, 47–87), 20 patients (80%) were women, and the median number of previous lines of therapy was 1 (range, 0–3). The exon 20 mutations were clustered between A763 and L777. The most common exon 20 mutations were p.(N771_H773dup) (n = 3) and p.(A767_V769dup) (n = 3). The ORR was 28% (95% CI, 12–49%), including seven partial responses, with a median DoR of 5.3 months (range, 2.7–27.6). The median PFS was 6.8 months (95% CI, 4.6–9.1) and the median OS was 15.2 months (95% CI, 14.3–16.0). The most common trAEs were diarrhea (72%), dry skin (44%), and fatigue (44%). The primary reason for discontinuation was progressive disease in 14 patients (56%). Conclusion: The POSITION20 study showed modest antitumor activity in patients with EGFRex20 + NSCLC treated with 160 mg osimertinib, with a confirmed ORR of 28% and acceptable toxicity.

Published
2022

37. High Dose Osimertinib in Patients with Advanced Stage EGFR Exon 20 Mutation-Positive NSCLC: Results from the Phase 2 Multicenter POSITION20 Trial

Author

Zwierenga, Fenneke, primary, van Veggel, Bianca, additional, Hendriks, Lizza E.L., additional, Hiltermann, T.Jeroen N., additional, Hiddinga, Birgitta I., additional, Hijmering – Kappelle, Lucie B.M., additional, ter Elst, Arja, additional, Hashemi, Sayed M.S., additional, Dingemans, A-M.C., additional, van der Leest, Cor, additional, de Langen, Adrianus J., additional, van den Heuvel, Michel, additional, and van der Wekken, Anthonie J., additional

Published
2022
Full Text
View/download PDF

39. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Author

van der Leest, Paul, primary, Hiddinga, Birgitta, additional, Miedema, Anneke, additional, Aguirre Azpurua, Maria L., additional, Rifaela, Naomi, additional, ter Elst, Arja, additional, Timens, Wim, additional, Groen, Harry J. M., additional, van Kempen, Léon C., additional, Hiltermann, T. Jeroen N., additional, and Schuuring, Ed, additional

Published
2021
Full Text
View/download PDF

41. Multicenter comparison of Molecular Tumor Boards in the Netherlands: definition, composition, methods and targeted therapy recommendations

Author

Pathologie Stafondersteuning, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, Longziekten, Infection & Immunity, Koopman, Bart, Groen, Harry J M, Ligtenberg, Marjolijn J L, Grünberg, Katrien, Monkhorst, Kim, de Langen, Adrianus J, Boelens, Mirjam C, Paats, Marthe S, von der Thüsen, Jan H, Dinjens, Winand N M, Solleveld, Nienke, van Wezel, Tom, Gelderblom, Hans, Hendriks, Lizza E, Speel, Ernst Jan M, Theunissen, Tom E, Kroeze, Leonie I, Mehra, Niven, Piet, Berber, van der Wekken, Anthonie J, Ter Elst, Arja, Timens, Wim, Willems, Stefan M, Meijers, Ruud W J, de Leng, Wendy W J, van Lindert, Anne S R, Radonic, Teodora, Hashemi, Sayed M S, Heideman, Daniëlle A M, Schuuring, Ed, van Kempen, Léon C, Pathologie Stafondersteuning, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, Longziekten, Infection & Immunity, Koopman, Bart, Groen, Harry J M, Ligtenberg, Marjolijn J L, Grünberg, Katrien, Monkhorst, Kim, de Langen, Adrianus J, Boelens, Mirjam C, Paats, Marthe S, von der Thüsen, Jan H, Dinjens, Winand N M, Solleveld, Nienke, van Wezel, Tom, Gelderblom, Hans, Hendriks, Lizza E, Speel, Ernst Jan M, Theunissen, Tom E, Kroeze, Leonie I, Mehra, Niven, Piet, Berber, van der Wekken, Anthonie J, Ter Elst, Arja, Timens, Wim, Willems, Stefan M, Meijers, Ruud W J, de Leng, Wendy W J, van Lindert, Anne S R, Radonic, Teodora, Hashemi, Sayed M S, Heideman, Daniëlle A M, Schuuring, Ed, and van Kempen, Léon C

Published
2021

43. Multicenter Comparison of Molecular Tumor Boards in The Netherlands:Definition, Composition, Methods, and Targeted Therapy Recommendations

Author

Koopman, Bart, Groen, Harry J.M., Ligtenberg, Marjolijn J.L., Grünberg, Katrien, Monkhorst, Kim, de Langen, Adrianus J., Boelens, Mirjam C., Paats, Marthe S., von der Thüsen, Jan H., Dinjens, Winand N.M., Solleveld, Nienke, van Wezel, Tom, Gelderblom, Hans, Hendriks, Lizza E., Speel, Ernst Jan M., Theunissen, Tom E., Kroeze, Leonie I., Mehra, Niven, Piet, Berber, van der Wekken, Anthonie J., ter Elst, Arja, Timens, Wim, Willems, Stefan M., Meijers, Ruud W.J., de Leng, Wendy W.J., van Lindert, Anne S.R., Radonic, Teodora, Hashemi, Sayed M.S., Heideman, Daniëlle A.M., Schuuring, Ed, van Kempen, Léon C., Koopman, Bart, Groen, Harry J.M., Ligtenberg, Marjolijn J.L., Grünberg, Katrien, Monkhorst, Kim, de Langen, Adrianus J., Boelens, Mirjam C., Paats, Marthe S., von der Thüsen, Jan H., Dinjens, Winand N.M., Solleveld, Nienke, van Wezel, Tom, Gelderblom, Hans, Hendriks, Lizza E., Speel, Ernst Jan M., Theunissen, Tom E., Kroeze, Leonie I., Mehra, Niven, Piet, Berber, van der Wekken, Anthonie J., ter Elst, Arja, Timens, Wim, Willems, Stefan M., Meijers, Ruud W.J., de Leng, Wendy W.J., van Lindert, Anne S.R., Radonic, Teodora, Hashemi, Sayed M.S., Heideman, Daniëlle A.M., Schuuring, Ed, and van Kempen, Léon C.

Abstract

Background: Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. Materials and Methods: MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy. Results: Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type–specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%). Conclusion: MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a “Dutch MTB model” for an optimal, collaborative, and nationally aligned MTB workflow. Implications for Practice: Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming

Published
2020

44. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles

Author

Koopman, Bart, primary, van der Wekken, Anthonie J., additional, ter Elst, Arja, additional, Hiltermann, T. Jeroen N., additional, Vilacha, Juliana F., additional, Groves, Matthew R., additional, van den Berg, Anke, additional, Hiddinga, Birgitta I., additional, Hijmering-Kappelle, Lucie B. M., additional, Stigt, Jos A., additional, Timens, Wim, additional, Groen, Harry J. M., additional, Schuuring, Ed, additional, and van Kempen, Léon C., additional

Published
2020
Full Text
View/download PDF

45. Abstract 4335: Clinical value of EGFR gene amplifications detected using amplicon based targeted next generation sequencing data in lung adenocarcinoma patients

Author

Meng, Pei, primary, Wei, Jiacong, additional, Terpstra, Miente Martijn, additional, van Rijk, Anke, additional, Tamminga, Menno, additional, Scherpen, Frank, additional, ter Elst, Arja, additional, Alimohamed, Mohamed Z., additional, Johansson, Lennart F., additional, Hiltermann, T. Jeroen N., additional, Groen, Harry J., additional, Kok, Klaas, additional, van der Wekken, Anthonie J., additional, and van den Berg, Anke, additional

Published
2020
Full Text
View/download PDF

46. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation

Author

Meng, Pei, primary, Koopman, Bart, additional, Kok, Klaas, additional, ter Elst, Arja, additional, Schuuring, Ed, additional, van Kempen, Léon C., additional, Timens, Wim, additional, Hiltermann, T. Jeroen N., additional, Groen, Harry J.M., additional, van den Berg, Anke, additional, and van der Wekken, Anthonie J., additional

Published
2020
Full Text
View/download PDF

48. Modeling of drug-protein interactions to support clinical decision making for therapy-resistant EGFR or ALK-positive non-small cell lung carcinoma

Author

Santos, Juliana F. Vilacha Madeira R., Hiddinga, Birgitta I., van Kempen, Leon C., ter Elst, Arja, Hijmering, Lucie B., Hiltermann, Thijo J., Schuuring, Ed, Groves, Matthew R., Groen, Harry J., van der Wekken, Anthonie J., Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Medicinal Chemistry and Bioanalysis (MCB), Drug Design, Translational Immunology Groningen (TRIGR), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Published
2019

50. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics

Author

Pathologie Laboratorium diagnostiek, Pathologie Pathologen staf, Cancer, Eijkelenboom, Astrid, Tops, Bastiaan B J, van den Berg, Anke, van den Brule, Adrianus J C, Dinjens, Winand N M, Dubbink, Hendrikus J, Ter Elst, Arja, Geurts-Giele, Willemina R R, Groenen, Patricia J T A, Groenendijk, Floris H, Heideman, Daniëlle A M, Huibers, Manon M H, Huijsmans, Cornelis J J, Jeuken, Judith W M, van Kempen, Léon C, Korpershoek, Esther, Kroeze, Leonie I, de Leng, Wendy W J, van Noesel, Carel J M, Speel, Ernst-Jan M, Vogel, Maartje J, van Wezel, Tom, Nederlof, Petra M, Schuuring, Ed, Ligtenberg, Marjolijn J L, Pathologie Laboratorium diagnostiek, Pathologie Pathologen staf, Cancer, Eijkelenboom, Astrid, Tops, Bastiaan B J, van den Berg, Anke, van den Brule, Adrianus J C, Dinjens, Winand N M, Dubbink, Hendrikus J, Ter Elst, Arja, Geurts-Giele, Willemina R R, Groenen, Patricia J T A, Groenendijk, Floris H, Heideman, Daniëlle A M, Huibers, Manon M H, Huijsmans, Cornelis J J, Jeuken, Judith W M, van Kempen, Léon C, Korpershoek, Esther, Kroeze, Leonie I, de Leng, Wendy W J, van Noesel, Carel J M, Speel, Ernst-Jan M, Vogel, Maartje J, van Wezel, Tom, Nederlof, Petra M, Schuuring, Ed, and Ligtenberg, Marjolijn J L

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results